SCHEMBL5402060

SCHEMBL5402060

CCOC(=O)C(CC(=O)c1ccc(-c2ccccc2)cc1)(NC(C)=O)C(=O)OCC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
RECQL P46063 1/20 0.60
ATM Q13315 2/20 0.51
POLB P06746 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
KDM4E B2RXH2 4/20 0.49
PKM P14618 2/20 0.49
THRB P10828 2/20 0.48
MAPT P10636 4/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
HTT P42858 2/20 0.47
HPGD P15428 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
TSHR P16473 2/20 0.43
TAAR1 Q96RJ0 1/20 0.43
AGTR1 P30556 1/20 0.43
ERCC5 P28715 1/20 0.42
FEN1 P39748 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5036126 0.92 ALDH1A1 (0.66) ALDH1A1RECQLATMPOLBNPSR1
SCHEMBL16143340 0.88 ALDH1A1 (0.57) ALDH1A1RECQLATMPOLBNPSR1
SCHEMBL16143372 0.86 ALDH1A1 (0.56) ALDH1A1RECQLATMPOLBNPSR1
SCHEMBL12912525 0.84 ALDH1A1 (0.52) ALDH1A1RECQLATMPOLBNPSR1
SCHEMBL7800751 0.83 ALDH1A1 (0.60) ALDH1A1RECQLATMKDM4EPKM
SCHEMBL13691613 0.82 ALDH1A1 (0.57) ALDH1A1RECQLATMPOLBNPSR1
SCHEMBL7797578 0.82 ALDH1A1 (0.50) ALDH1A1RECQLATMPOLBNPSR1
SCHEMBL16143378 0.82 ALDH1A1 (0.46) ALDH1A1RECQLATMPOLBNPSR1
SCHEMBL1925793 0.80 POLB (0.58) ALDH1A1POLBNPSR1KDM4EMAPT
SCHEMBL6506349 0.80 ALDH1A1 (0.64) ALDH1A1RECQLATMKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1511473-B1 BIS-AROMATIC ALKANOLS NOVARTIS AG (CH) 2013-04-17 EP disclosed
US-7169817-B2 Bis-aromatic alkanols IRM LLC (BM) 2007-01-30 US disclosed
EP-1511473-A2 BIS-AROMATIC ALKANOLS Novartis AG (CH) 2005-03-09 EP disclosed
US-20040048857-A1 Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. IRM LLC (BM) 2004-03-11 US disclosed
WO-2003099192-A2 BIS-AROMATIC ALKANOLS NOVARTIS AG (CH) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048857-A1 Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. CD4, HLA-DRB1, MALT1 ALDH1A1 1177/4885RECQL 1702/4885ATM 3515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.